



Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages


Roger R. Nani, Alexander P. Gorka, Tadanobu Nagaya, Hisataka Kobayashi, and Martin J. Schnermann*

Abstract: Despite significant progress in the clinical application of antibody drug conjugates (ADCs), novel cleavage strategies that provide improved selectivity are still needed. Herein is reported the first approach that uses near-IR light to cleave a small molecule from a biomacromolecule, and its application to the problem of ADC linkage. The preparation of cyanine antibody conjugates, drug cleavage mediated by 690 nm light, and initial *in vitro* and *in vivo* evaluation is described. These studies provide the critical chemical underpinning from which to develop this near-IR light cleavable linker strategy.

The recent success of antibody-drug conjugates (ADCs) has validated the benefits of combining macromolecule and small molecule therapeutics.^[1–4] Within this exciting area, a remaining challenge is to identify linker strategies that provide improved spatiotemporal control of the pivotal drug release step. Existing approaches (Figure 1A) rely on endogenous reactions with little inherent tumor selectivity.^[5,6] As a consequence, undesirable release in circulation can be a significant issue.^[7,8] Moreover, benign tissue uptake of the antibody, through either antigen-specific or antigen-independent mechanisms, can lead to off-target drug release.^[9,10] An appealing solution would be to develop antibody-drug cleavage chemistry that relies on an external stimulus that can be applied in a site-specific fashion.

Light in the near-IR range (650–900 nm) has unique potential in this context. These wavelengths exhibit significant tissue penetration, minimal toxicity, and are clinically validated for both diagnostic and therapeutic applications.^[11] Near-IR fluorescence imaging is routine in laboratory and certain clinical contexts. Innovative applications, such as methods to optically define tumor margins during surgery, are being developed and clinically translated.^[12,13] Light-based therapeutic modalities using phototoxic small molecules have an extensive history in the treatment of cancer and skin disorders.^[14,15] Recent advances, including antibody-based

A. Antibody-Drug Conjugate Linker Strategies



B. Cyanine-Based Near-IR Cleavable Linker - Design and Mechanism




Figure 1. A) Overview and B) design and mechanism of a cyanine-based near-IR light cleavable ADC.

photoimmunotherapy (PIT) strategies, are providing new therapeutic avenues in this area.^[16,17]

We recently introduced a near-IR uncaging strategy using the heptamethine cyanine fluorophore scaffold as the caging component.^[18] The reaction sequence reveals a secondary amine through photooxidation of the cyanine polyene followed by C4'-N bond hydrolysis. A final urea-forming cyclization releases a pendant phenol (Figure 1B). The photooxidative C-C cleavage process entails reaction of cyanine-photosensitized singlet oxygen with the polyene to form thermally labile dioxetane intermediates.^[19,20]

Herein we apply this cyanine photocaging strategy in the first approach to use near-IR light to cleave a small molecule from a protein or other biological macromolecule.^[21] There have been several recent advances in the area of light-mediated drug delivery, including steps toward using tissue-compatible longer wavelengths.^[22–34] The strategy reported herein has promising characteristics: initiation with 690 nm light, the traceable emissive properties of the cyanine scaffold, and the use of broadly employed monoclonal

[*] Dr. R. R. Nani,^[+] Dr. A. P. Gorka,^[+] Dr. M. J. Schnermann
Chemical Biology Laboratory, Center for Cancer Research
National Cancer Institute, Frederick, MD (USA)
E-mail: martin.schnermann@nih.gov

Dr. T. Nagaya, Dr. H. Kobayashi
Molecular Imaging Program, Center for Cancer Research
National Cancer Institute, Bethesda, MD (USA)

[+] These authors contributed equally to this work.


Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201507391>.

antibodies. The synthesis of the bioconjugatable cyanine photocage, characterization of the uncaging reaction, and cellular evaluation are described. In vivo imaging of the resulting antibody conjugate confirms its excellent tumor uptake and that the fluorescent signal can be depleted with external irradiation.

We have prepared bioconjugatable variants of caged 6,8-difluoro-4-methyl-umbelliferone (Umb), a useful fluorescence reporter, and combretastatin A4 (CA4), a potent inhibitor of microtubule polymerization.^[35,36] Our linker strategy uses the carbamate functional group as the antibody attachment point. This design ensures that small molecule release from the antibody is the last step in the light-initiated reaction sequence. The synthesis of the NHS esters commenced from commercially available IR-783 (**1**, Figure 2 A). Compound **2**, available in four steps from commercial materials, undergoes C4'-substitution in high yield (81 %) to afford **3**.^[37] Initial studies on the Boc removal/carbamate formation sequence revealed that many conditions provided an approximately 1:1 mixture of two distinct *N*-linked cyanine products. Further analysis revealed these to be constitutional isomers comprising the desired C4'-*N*-linkage, **4**, and the isomer arising from the intermediate diamine equilibrating through C4' addition/elimination sequences prior to carbamate formation (Supporting Information, Figure S1). Of note, intramolecular electrophilic reactivity involving the C4' position of heptamethine cyanines has been observed elsewhere.^[38,39] It was ultimately determined that deprotection of the Boc group in neat TFA, aqueous bicarbonate quench at -10 °C, and addition of the respective chloroformate to the cooled mixture provided **4a,b** in excellent yields (78 % and 93 %, respectively). Copper-catalyzed [3+2] cycloaddition of **4a,b** with azido-PEG₄-acid **5** and transformation of the acid to the NHS ester with TSTU (**6**) provided the fully functionalized cyanines **7a,b** in high yield. As a negative control, we also prepared a variant of **7** where CA4 and Umb were replaced with phenol (see the Supporting Information).

The efficient preparation of **7a,b** allowed us to investigate the antibody conjugation and cleavage chemistry. We have used panitumumab (Pan), a clinical monoclonal antibody to human epidermal growth factor receptor (EGFR). Pan was incubated with 1.3 equivalents of NHS ester **7a,b** in pH 8.5 buffer to provide the CY-Pan-Umb and CY-Pan-CA4 conjugates after size-exclusion chromatography (Supporting Information, Figure S2). The purity of both conjugates was confirmed by SDS-PAGE (Supporting Information, Figure S3). A solution of CY-Pan-Umb in pH 7.4 PBS was irradiated with 50 J of 690 nm light (33 min at 25 mWcm⁻²) administered from a convenient LED source at 25 °C, or maintained in the dark, and then Umb fluorescence was monitored while heating at 37 °C (Figure 2 B). The Umb fluorescence increase was only observed in the irradiated sample with a half-life for the release reaction (*t*_{1/2}) of 67 min. Suggesting this process will tolerate the acidic environment of the lysosome, adjusting the pH to 5.0 only moderately reduces the rate of release (*t*_{1/2} = 105 min; Supporting Information, Figure S4). CY-Pan-CA4 was similarly irradiated with 50 J of 690 nm light or not, and then the yield of CA4 was monitored by HPLC following incubation (without additional irradiation) at 37 °C. The irradiated sample provided quite useful yields of free CA4, whereas the unirradiated sample provided only negligible quantities of the free drug (Figure 2 B). Notably, incubation of CY-Pan-CA4 in human plasma at 37 °C also led to minimal release of CA4 (< 1 %) after 72 h (Supporting Information, Figure S5). We also examined the absorption and fluorescence emission of the conjugate and the consequence of irradiation on the latter. The CY-Pan-

A. Synthesis of Bioconjugatable Cyanine Photocages



B. Bioconjugation and Small Molecule Release




Figure 2. Synthesis of conjugates and characterization of 690 nm light-initiated drug release. A) Synthesis of **7a,b**. B) Conjugation of **7a,b** to Pan, uncaging to yield fluorescent Umb, and yield of CA4 in the presence and absence of 690 nm irradiation (50 J).

tion) at 37 °C. The irradiated sample provided quite useful yields of free CA4, whereas the unirradiated sample provided only negligible quantities of the free drug (Figure 2 B). Notably, incubation of CY-Pan-CA4 in human plasma at 37 °C also led to minimal release of CA4 (< 1 %) after 72 h (Supporting Information, Figure S5). We also examined the absorption and fluorescence emission of the conjugate and the consequence of irradiation on the latter. The CY-Pan-

CA4 conjugate maintains the near-IR optical properties of the carboxylic acid precursor to **7b** ($\lambda_{\text{abs}} = 700 \text{ nm}$, $\lambda_{\text{em}} = 795 \text{ nm}$; Supporting Information, Figure S6). Irradiation using 690 nm light reduced the emission of CY-Pan-CA4 (Supporting Information, Figure S7), with little remaining fluorescence after the 50 J of light fluence used for drug release. This result suggests that irradiation-induced loss of emission could serve as useful marker for drug release.

We characterized the CY-Pan-CA4 conjugate in an *in vitro* context. Fluorescence confocal microscopy using EGFR+ (MDA-MB-468) and EGFR- (MCF-7) cells revealed that only the former exhibited characteristic antibody labeling (Supporting Information, Figure S8). This specific cellular labeling was also confirmed using fluorescence activated cell sorting (FACS; Supporting Information, Figure S9). Together, these results indicate that the binding specificity of Pan is preserved in the immunoconjugate. We next assessed whether CY-Pan-CA4 elicits a cytotoxic effect in these same cell lines in a light- and antigen-dependent fashion. We first determined cell viability with continuous exposure to a wide concentration range of CY-Pan-CA4 to examine the full biological effect of cleaved versus uncleaved conjugate. Irradiation of cells in the presence of CY-Pan-CA4 with 30 J of 690 nm light led to a growth inhibitory activity ($\text{IC}_{50} = 16 \text{ nM}$) that nearly matched that of CA4 alone ($\text{IC}_{50} = 11 \text{ nM}$; Figure 3A). By contrast, the absence of irradiation significantly diminished this growth inhibitory effect ($\text{IC}_{50} = 1.1 \mu\text{M}$), providing additional evidence for the high dark stability of the conjugated form. Finally, as expected, the antibody alone had no effect on cell viability over the concentration range examined ($\text{IC}_{50} > 2 \mu\text{M}$). We also evaluated the internalized and cell-surface bound antibody fraction. MDA-MB-468 (EGFR+) and MCF-7 (EGFR-) cells were incubated with CY-Pan-CA4 (100 nM) for 24 h, the media was replaced, irradiation was carried out as above, and cell viability was evaluated. A significant reduction in cell viability was observed only upon 690 nm irradiation in the EGFR+ cell line, with little effect in either the EGFR- cell line or in the absence of irradiation (Figure 3B). Finally, no effect on viability was apparent using a version of the antibody conjugate that releases only biologically inactive phenol, indicating that the observed cytotoxicity is solely a consequence of drug release (Supporting Information, Figure S10).

CY-Pan-CA4 is likely not suitable to address tumor burden *in vivo*, as the potency of CA4 does not match that of typical ADC payloads.^[40] However, we have carried out *in vivo* imaging studies that sought to assess conjugate stability, tumor localization, and if external irradiation could modulate the fluorescent signal. To examine the biodistribution of the CY-Pan-CA4 conjugate, we used a xenograft tumor model with dorsal A431 (EGFR+) tumors. After tail vein injection of CY-Pan-CA4 (100 μg), we visualized the conjugate using an 800 nm emission channel. Significant selective tumor accumulation was observed, with high tumor-to-background ratios between 1–7 days (maximal between 2–3 days; Supporting Information, Figures S11 and S12). To evaluate the effect of irradiation on the fluorescent signal, we implanted mice with two tumors, one in each side of the




Figure 3. *In vitro* and *in vivo* analysis of CY-Pan-CA4. A) Light-dependent (690 nm, 30 J) cytotoxicity of CY-Pan-CA4, CA4, and Pan against MDA-MB-468 cells (continuous dose). B) Light-dependent (690 nm, 30 J) cytotoxicity of internalized CY-Pan-CA4, CA4, and Pan against MDA-MB-468 and MCF-7 cells (media exchange). C) Serial fluorescence images of A431 tumors (implanted in both sides of the dorsum) pre- and post-irradiation with various doses of near-IR light at two days post-injection. Only the right tumor was irradiated; the left tumor was covered with aluminum foil. * $p = 0.03$, ** $p = 0.001$, *** $p < 0.0001$.

dorsum, administered CY-Pan-CA4 as above, and, after 2 days, irradiated one of the tumors with increasing light doses from a 690 nm laser (500 mW cm^{-2}). The fluorescence of only the irradiated tumor decreased in a light-dependent manner, with 100 J (3.3 min irradiation) nearly ablating the signal (Figure 3C). Notably, the light doses applied here are similar to or compare favorably to those required for conventional photodynamic therapy-type applications.^[41]

These studies are the first to use near-IR light to initiate small molecule/therapeutic protein cleavage. Given the widespread use of near-IR optical tools in clinical and basic science settings, this approach should enable highly targeted, timed delivery of bioactive small molecules in complex settings. Suggesting theranostic applications, the fluorescence signal provides a useful marker for target accumulation and the loss of that signal can indicate drug release.^[42] Future inquiries will

include alternative drug payloads, as well as the choice of antibody and labeling method, which are critical issues with all ADC strategies. These efforts will be coupled with insights gained in ongoing structural optimization studies seeking to increase the kinetics and quantum efficiency of the cyanine photocaging reaction.

Acknowledgements

We thank Dr. Joseph Barchi for NMR assistance and Dr. James Kelley for mass spectrometric analysis. We thank the Optical Microscopy and Analysis Laboratory (Center for Cancer Research, NCI Frederick) for assistance in obtaining confocal fluorescence images and the CCR Flow Cytometry Core (Cancer and Inflammation Program, Center for Cancer Research, NCI-Frederick) for help with flow cytometry analysis. We thank Mr. James Shaum for synthesis of Umb. This work was supported by the Intramural Research Program of the National Institutes of Health, Center for Cancer Research, and the National Cancer Institute, National Institutes of Health.

Keywords: antibodies · conjugation · cyanines · drug delivery · fluorescence

How to cite: *Angew. Chem. Int. Ed.* **2015**, *54*, 13635–13638
Angew. Chem. **2015**, *127*, 13839–13842

- [1] S. C. Alley, N. M. Okeley, P. D. Senter, *Curr. Opin. Chem. Biol.* **2010**, *14*, 529–537.
- [2] R. V. Chari, M. L. Miller, W. C. Widdison, *Angew. Chem. Int. Ed.* **2014**, *53*, 3796–3827; *Angew. Chem.* **2014**, *126*, 3872–3904.
- [3] H. L. Perez, P. M. Cardarelli, S. Deshpande, S. Gangwar, G. M. Schroeder, G. D. Vite, R. M. Borzilleri, *Drug Discovery Today* **2014**, *19*, 869–881.
- [4] G. Casi, D. Neri, *J. Controlled Release* **2012**, *161*, 422–428.
- [5] L. Ducry, B. Stump, *Bioconjugate Chem.* **2010**, *21*, 5–13.
- [6] J. A. Flygare, T. H. Pillow, P. Aristoff, *Chem. Biol. Drug Des.* **2013**, *81*, 113–121.
- [7] R. J. Sanderson, M. A. Hering, S. F. James, M. M. Sun, S. O. Doronina, A. W. Siadak, P. D. Senter, A. F. Wahl, *Clin. Cancer Res.* **2005**, *11*, 843–852.
- [8] M. Dorywalska, P. Strop, J. A. Melton-Witt, A. Hasa-Moreno, S. E. Farias, M. Galindo Casas, K. Delaria, V. Lui, K. Poulsen, C. Loo, S. Krimm, G. Bolton, L. Moine, R. Dushin, T. T. Tran, S. H. Liu, M. Rickert, D. Foletti, D. L. Shelton, J. Pons, A. Rajpal, *Bioconjugate Chem.* **2015**, *26*, 650–659.
- [9] B. Gorovits, C. Krinos-Fiorotti, *Cancer Immunol. Immunother.* **2013**, *62*, 217–223.
- [10] H. K. Erickson, J. M. Lambert, *AAPS J.* **2012**, *14*, 799–805.
- [11] R. Weissleder, *Nat. Biotechnol.* **2001**, *19*, 316–317.
- [12] Q. T. Nguyen, R. Y. Tsien, *Nat. Rev. Cancer* **2013**, *13*, 653–662.
- [13] G. M. van Dam, G. Themelis, L. M. A. Crane, N. J. Harlaar, R. G. Pleijhuis, W. Kelder, A. Sarantopoulos, J. S. de Jong, H. J. G. Arts, A. G. J. van der Zee, J. Bart, P. S. Low, V. Ntziachristos, *Nat. Med.* **2011**, *17*, 1315.
- [14] D. E. Dolmans, D. Fukumura, R. K. Jain, *Nat. Rev. Cancer* **2003**, *3*, 380–387.
- [15] M. Ethirajan, Y. H. Chen, P. Joshi, R. K. Pandey, *Chem. Soc. Rev.* **2011**, *40*, 340–362.
- [16] M. Mitsunaga, M. Ogawa, N. Kosaka, L. T. Rosenblum, P. L. Choyke, H. Kobayashi, *Nat. Med.* **2011**, *17*, 1685–1691.
- [17] B. Q. Spring, A. O. Abu-Yousif, A. Palanisami, I. Rizvi, X. Zheng, Z. Mai, S. Anbil, R. B. Sears, L. B. Mensah, R. Goldschmidt, S. S. Erdem, E. Oliva, T. Hasan, *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E933–942.
- [18] A. P. Gorka, R. R. Nani, J. Zhu, S. Mackem, M. J. Schnermann, *J. Am. Chem. Soc.* **2014**, *136*, 14153–14159.
- [19] A. P. Gorka, R. R. Nani, M. J. Schnermann, *Org. Biomol. Chem.* **2015**, *13*, 7584.
- [20] R. R. Nani, J. A. Kelley, J. Ivanic, M. J. Schnermann, *Chem. Sci.* **2015**, DOI: 10.1039/C5SC02396C.
- [21] We are only aware of a single prior report of light-mediated ADC cleavage using UV or visible wavelengths, although the structure of the linker was not reported: C. W. Gilbert, E. B. McGowan, G. B. Seery, K. S. Black, M. D. J. Pegram, *J. Exp. Ther. Oncol.* **2003**, *3*, 27–35.
- [22] J. Broichhagen, J. A. Frank, D. Trauner, *Acc. Chem. Res.* **2015**, *48*, 1947–1960.
- [23] M. Bio, P. Rajaputra, G. Nkepan, S. G. Awuah, A. M. L. Hossion, Y. You, *J. Med. Chem.* **2013**, *56*, 3936–3942.
- [24] G. Nkepan, M. Bio, P. Rajaputra, S. G. Awuah, Y. You, *Bioconjugate Chem.* **2014**, *25*, 2175–2188.
- [25] T. A. Shell, J. R. Shell, Z. L. Rodgers, D. S. Lawrence, *Angew. Chem. Int. Ed.* **2014**, *53*, 875–878; *Angew. Chem.* **2014**, *126*, 894–897.
- [26] S. Samanta, A. A. Beharry, O. Sadoski, T. M. McCormick, A. Babalhavaeji, V. Tropepe, G. A. Woolley, *J. Am. Chem. Soc.* **2013**, *135*, 9777–9784.
- [27] S. Helmy, F. A. Leibfarth, S. Oh, J. E. Poelma, C. J. Hawker, J. Read de Alaniz, *J. Am. Chem. Soc.* **2014**, *136*, 8169–8172.
- [28] K. A. Carter, S. Shao, M. I. Hoopes, D. Luo, B. Ahsan, V. M. Grigoryants, W. Song, H. Huang, G. Zhang, R. K. Pandey, J. Geng, B. A. Pfeifer, C. P. Scholes, J. Ortega, M. Karttunen, J. F. Lovell, *Nat. Commun.* **2014**, *5*, 3546.
- [29] Q. Lin, Q. Huang, C. Li, C. Bao, Z. Liu, F. Li, L. Zhu, *J. Am. Chem. Soc.* **2010**, *132*, 10645–10647.
- [30] C. J. Carling, M. L. Viger, V. A. N. Huu, A. V. Garcia, A. Almutairi, *Chem. Sci.* **2015**, *6*, 335–341.
- [31] L. A. Antony, T. Slanina, P. Sebej, T. Solomek, P. Klan, *Org. Lett.* **2013**, *15*, 4552–4555.
- [32] N. Umeda, H. Takahashi, M. Kamiya, T. Ueno, T. Komatsu, T. Terai, K. Hanaoka, T. Nagano, Y. Urano, *ACS Chem. Biol.* **2014**, *9*, 2242–2246.
- [33] N. Rubinstein, P. Liu, E. W. Miller, R. Weinstein, *Chem. Commun.* **2015**, *51*, 6369–6372.
- [34] P. P. Goswami, A. Syed, C. L. Beck, T. R. Albright, K. M. Mahoney, R. Unash, E. A. Smith, A. H. Winter, *J. Am. Chem. Soc.* **2015**, *137*, 3783–3786.
- [35] G. Nagaiah, S. C. Remick, *Future Oncol.* **2010**, *6*, 1219–1228.
- [36] M. Borowiak, W. Nahaboo, M. Reynders, K. Nekolla, P. Jalinot, J. Hasserodt, M. Rehberg, M. Delattre, S. Zahler, A. Vollmar, D. Trauner, O. Thorn-Seshold, *Cell* **2015**, *162*, 403–411.
- [37] L. Strekowski, M. Lipowska, G. Patonay, *J. Org. Chem.* **1992**, *57*, 4578–4580.
- [38] R. R. Nani, J. B. Shaum, A. P. Gorka, M. J. Schnermann, *Org. Lett.* **2015**, *17*, 302–305.
- [39] S. Y. Lim, K. H. Hong, D. I. Kim, H. Kwon, H. J. Kim, *J. Am. Chem. Soc.* **2014**, *136*, 7018–7025.
- [40] J. Anderl, H. Faulstich, T. Hechler, M. Kulke, *Methods Mol. Biol.* **2003**, *1045*, 51–70.
- [41] Z. Huang, *Technol. Cancer Res. Treat.* **2005**, *4*, 283–293.
- [42] P. Rai, S. Mallidi, X. Zheng, R. Rahmzadeh, Y. Mir, S. Elrington, A. Khurshid, T. Hasan, *Adv. Drug Delivery Rev.* **2010**, *62*, 1094–1124.

Received: August 8, 2015

Published online: September 22, 2015